Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer

  Free Subscription


Articles published in J Urol

Retrieve available abstracts of 189 articles:
HTML format



Single Articles


    July 2022
  1. SONG Y, Du Y, Qin C, Bai F, et al
    Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. Letter.
    J Urol. 2022;208:222-223.
    PubMed    


    June 2022
  2. GESSNER KH, Siemens DR, Bjurlin MA
    Re: Does Smoking Cessation Reduce Bladder Cancer Recurrence?
    J Urol. 2022 Jun 21:101097JU0000000000002832. doi: 10.1097/JU.0000000000002832.
    PubMed    


  3. ROSEN GH, Nallani A, Muzzey C, Murray KS, et al
    Antegrade Instillation of UGN-101 (Mitomycin for Pyelocalyceal Solution) for Low-Grade Upper Tract Urothelial Carcinoma: Initial Clinical Experience.
    J Urol. 2022;207:1302-1311.
    PubMed     Abstract available


    May 2022
  4. STOVER AM, Basak R, Mueller D, Lipman R, et al
    Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2022 May 31:101097JU0000000000002747. doi: 10.1097/JU.0000000000002747.
    PubMed     Abstract available


  5. KATES M, Mansour AM, Lamm DL, Shore N, et al
    Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Non-muscle Invasive Bladder Cancer.
    J Urol. 2022 May 16:101097JU0000000000002778. doi: 10.1097/JU.0000000000002778.
    PubMed     Abstract available


  6. HUELSTER HL, Sexton WJ
    Real-World Outcomes Driving the Needle toward Simplification of Nonmuscle Invasive Bladder Cancer Risk Stratification.
    J Urol. 2022 May 2:101097JU0000000000002731. doi: 10.1097/JU.0000000000002731.
    PubMed    



  7. Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer.
    J Urol. 2022;207:1166.
    PubMed    


  8. MASTROIANNI R, Ferriero M, Tuderti G, Anceschi U, et al
    Open Radical Cystectomy versus Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Early Outcomes of a Single-Center Randomized Controlled Trial.
    J Urol. 2022;207:982-992.
    PubMed     Abstract available


    April 2022
  9. SONG Y, Du Y, Qin C, Xu T, et al
    The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-Analysis. Letter.
    J Urol. 2022;207:937.
    PubMed    


  10. YANAGISAWA T, Mori K, Motlagh RS, Kawada T, et al
    En Bloc Resection for Bladder Tumors: An Updated Systematic Review and Meta-Analysis of Its Differential Effect on Safety, Recurrence and Histopathology.
    J Urol. 2022;207:754-768.
    PubMed     Abstract available


  11. MATIN SF, Pierorazio PM, Kleinmann N, Gore JL, et al
    Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report.
    J Urol. 2022;207:779-788.
    PubMed     Abstract available


  12. RICHTER LA, Osazuwa-Peters OL, Routh JC, Handa VL, et al
    Vaginal Complications after Cystectomy: Results from a Medicare Sample.
    J Urol. 2022;207:789-796.
    PubMed     Abstract available


    March 2022
  13. GESSNER KH, Siemens DR, Bjurlin MA
    Does Smoking Cessation Reduce Bladder Cancer Recurrence?
    J Urol. 2022 Mar 15:101097JU0000000000002649. doi: 10.1097/JU.0000000000002649.
    PubMed    


    February 2022
  14. MITRA AP, Cai J, Miranda G, Bhanvadia S, et al
    Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases.
    J Urol. 2022;207:302-313.
    PubMed     Abstract available


  15. MIEST T, Khanna A, Sharma V, Hensley PJ, et al
    Development and Validation of a Risk-Adapted Scoring Model for Metachronous Upper Tract Urothelial Carcinoma following Radical Cystectomy.
    J Urol. 2022;207:284-292.
    PubMed     Abstract available


    January 2022
  16. FURBERG H, Petruzella S, Whiting K, Stein E, et al
    Association of Biochemically Verified Post-diagnosis Smoking and Non-muscle Invasive Bladder Cancer Recurrence Risk.
    J Urol. 2022 Jan 27:101097JU0000000000002449. doi: 10.1097/JU.0000000000002449.
    PubMed     Abstract available


  17. MONAGHAN TF, Wagg AS, Rahman SN, Winer AG, et al
    Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes following Radical Cystectomy. Letter.
    J Urol. 2022;207:237-238.
    PubMed    


  18. CHESNUT GT, Goh AC
    Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes following Radical Cystectomy. Reply.
    J Urol. 2022;207:238-239.
    PubMed    


  19. GOLD SA, Kenigsberg AP, Lotan Y
    Diagnostic and Cost Implications of the 2020 AUA Microhematuria Guidelines: Modeling Impact in a Large Public Health Care System.
    J Urol. 2022;207:52-60.
    PubMed     Abstract available


    December 2021
  20. RIVEROS C, Jazayeri SB, Chalfant V, Ahmed F, et al
    The Geriatric Nutritional Risk Index Predicts Postoperative Outcomes in Bladder Cancer: A Propensity Score-Matched Analysis.
    J Urol. 2021 Dec 2:101097JU0000000000002342. doi: 10.1097/JU.0000000000002342.
    PubMed     Abstract available


  21. KHALEEL S, Regmi S, Hannah P, Watarai B, et al
    Impact of Preoperative Immunonutrition on Perioperative Outcomes Following Cystectomy. Reply.
    J Urol. 2021;206:1531-1532.
    PubMed    


  22. ALSYOUF M, Djaladat H
    Impact of Preoperative Immunonutrition on Perioperative Outcomes following Cystectomy. Letter.
    J Urol. 2021;206:1530-1531.
    PubMed    


  23. RAMAN JD, Kavalieris L, Konety B, Porten S, et al
    The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma.
    J Urol. 2021;206:1380-1389.
    PubMed     Abstract available


  24. YANKELEVICH GR, Dreher PC, Taylor Z, Kim D, et al
    Socio-Environmental Conditions Associated with Geospatial Clusters of Urothelial Carcinoma: A Multi-Institutional Analysis.
    J Urol. 2021;206:1390-1402.
    PubMed     Abstract available


    November 2021
  25. MICHAEL J, Matulewicz RS, Bjurlin MA
    Assessment of Tobacco Screening and Smoking Cessation Recommendations Among Bladder Cancer Guidelines: A Call to Action.
    J Urol. 2021 Nov 30:101097JU0000000000002360. doi: 10.1097/JU.0000000000002360.
    PubMed    


  26. OEFELEIN MG
    The Continued Importance of Transurethral Resection of Bladder Tumor (TURBT) in the Treatment of Bladder Cancer.
    J Urol. 2021 Nov 5:101097JU0000000000002325. doi: 10.1097/JU.0000000000002325.
    PubMed    


  27. KHALEEL S, Regmi S, Hannah P, Watarai B, et al
    Impact of Preoperative Immunonutrition on Perioperative Outcomes following Cystectomy.
    J Urol. 2021;206:1132-1138.
    PubMed     Abstract available


  28. HENSLEY PJ, Bree KK, Campbell MT, Alhalabi O, et al
    Progression of Disease after Bacillus Calmette-Guerin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy.
    J Urol. 2021;206:1258-1267.
    PubMed     Abstract available


  29. SCHUETTFORT VM, Pradere B, D'Andrea D, Grossmann NC, et al
    Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy.
    J Urol. 2021;206:1122-1131.
    PubMed     Abstract available


    October 2021
  30. CHAPPIDI MR, Yang H, Meng MV, Bivalacqua TJ, et al
    Utility of Blue Light Cystoscopy for Post-BCG Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons.
    J Urol. 2021 Oct 25:101097JU0000000000002308. doi: 10.1097/JU.0000000000002308.
    PubMed     Abstract available


  31. BREE KK, Navai N
    Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. Reply.
    J Urol. 2021 Oct 25:101097JU0000000000002307. doi: 10.1097/JU.0000000000002307.
    PubMed    


  32. DE LA CALLE CM, Patel SH, Kates M
    Contemporary Rates of Gynecologic Organ Involvement in Females With Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. Letter.
    J Urol. 2021 Oct 25:101097JU0000000000002306. doi: 10.1097/JU.0000000000002306.
    PubMed    


  33. KHANNA A, Miest T, Sharma V, Campbell R, et al
    Role of Lymphadenectomy During Radical Cystectomy for Non-muscle Invasive Bladder Cancer: Results From a Multi-Institutional Experience.
    J Urol. 2021 Oct 25:101097JU0000000000002266. doi: 10.1097/JU.0000000000002266.
    PubMed     Abstract available


  34. LOTAN Y, de Jong J, Liu VYT, Bismar TA, et al
    Patients With Muscle Invasive Bladder Cancer with Non-luminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy.
    J Urol. 2021 Oct 13:101097JU0000000000002261. doi: 10.1097/JU.0000000000002261.
    PubMed     Abstract available


  35. GHOREIFI A, Douglawi A, Djaladat H
    The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-analysis. Letter.
    J Urol. 2021;206:1071.
    PubMed    


  36. SHARMA V, Miest TS, Chamie K, Matin SF, et al
    The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-analysis. Reply.
    J Urol. 2021;206:1072.
    PubMed    


  37. KHANNA A, Zganjar A, Lyon T, Shah P, et al
    A Contemporary Analysis of Urethral Recurrence following Radical Cystectomy.
    J Urol. 2021;206:970-977.
    PubMed     Abstract available


    September 2021
  38. CARY C, Tong Y, Linsell S, Ghani K, et al
    Ranking Important Factors for Using Postoperative Chemotherapy in Non-Muscle Invasive Bladder Cancer: Conjoint Analysis Results From the Michigan Urological Surgery Improvement Collaborative (MUSIC).
    J Urol. 2021 Sep 23:101097JU0000000000002233. doi: 10.1097/JU.0000000000002233.
    PubMed     Abstract available


  39. WETTSTEIN MS, Baxter NN, Sutradhar R, Mamdani M, et al
    Factors Associated with Re-resection in T1 Bladder Cancer: Identifying Patients Who do Not Receive Guideline-Concordant Care at the Population Level.
    J Urol. 2021 Sep 22:101097JU0000000000002229. doi: 10.1097/JU.0000000000002229.
    PubMed     Abstract available


  40. MONTORSI F, Moschini M, Necchi A, Deho F, et al
    Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guerin. Letter.
    J Urol. 2021 Sep 14:101097JU0000000000002237. doi: 10.1097/JU.0000000000002237.
    PubMed    


  41. HENSLEY PJ, Kamat AM
    Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guerin. Response.
    J Urol. 2021 Sep 14:101097JU0000000000002238. doi: 10.1097/JU.0000000000002238.
    PubMed    


  42. HENSLEY PJ, Kamat AM
    Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin: Implications for Clinical Trial Design. Reply.
    J Urol. 2021 Sep 2:101097JU0000000000002238. doi: 10.1097/JU.0000000000002238.
    PubMed    


  43. SHARMA V, Miest TS, Juvet TS, Toussi A, et al
    The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-Analysis.
    J Urol. 2021;206:558-567.
    PubMed     Abstract available


  44. PETROS FG, Choi W, Qi Y, Moss T, et al
    Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma.
    J Urol. 2021;206:548-557.
    PubMed     Abstract available


  45. KATIMS AB, Say R, Derweesh I, Uzzo R, et al
    Risk Factors for Intravesical Recurrence after Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Cancer (ROBUUST Collaboration).
    J Urol. 2021;206:568-576.
    PubMed     Abstract available


    August 2021
  46. D'ANDREA D, Black PC, Zargar H, Dinney CP, et al
    Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle-Invasive Bladder Cancer.
    J Urol. 2021 Aug 27:101097JU0000000000002190. doi: 10.1097/JU.0000000000002190.
    PubMed     Abstract available


  47. PATEL HD, Patel SH, Blanco-Martinez E, Kuzbel J, et al
    Four versus Three Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathologic Response and Survival.
    J Urol. 2021 Aug 27:101097JU0000000000002189. doi: 10.1097/JU.0000000000002189.
    PubMed     Abstract available


  48. CHEVLI KK, Shore ND, Trainer A, Smith AB, et al
    Primary Chemoablation of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Using UGN-102, A Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.
    J Urol. 2021 Aug 26:101097JU0000000000002186. doi: 10.1097/JU.0000000000002186.
    PubMed     Abstract available


  49. MERSEBURGER AS, Castellano D, Powles T, Loriot Y, et al
    Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.
    J Urol. 2021;206:240-251.
    PubMed     Abstract available


  50. PATEL SR, Lerner SP
    Novel Thermo-Sensitive Hydrogel Therapy for Low-Grade Upper Tract Urothelial Carcinoma.
    J Urol. 2021;206:191-193.
    PubMed    


    July 2021
  51. SCHOENBERG M, Steinberg G
    Rethinking the Treatment of Recurrent Nonmuscle-Invasive Bladder Cancer.
    J Urol. 2021;206:7-9.
    PubMed    


  52. PIERETTI A, Krasnow R, Drumm M, Gusev A, et al
    Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy.
    J Urol. 2021;206:29-36.
    PubMed     Abstract available


    June 2021
  53. ZHANG R, Zang J, Xie F, Zhang Y, et al
    Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
    J Urol. 2021 Jun 1:101097JU0000000000001878. doi: 10.1097/JU.0000000000001878.
    PubMed     Abstract available


    May 2021
  54. CHAKIRYAN NH, Jiang DD, Gillis KA, Green E, et al
    Pathologic Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
    J Urol. 2021 May 25:101097JU0000000000001855. doi: 10.1097/JU.0000000000001855.
    PubMed     Abstract available


  55. MARTINI A, Afferi L, Zamboni S, Schultz JG, et al
    Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy.
    J Urol. 2021 May 25:101097JU0000000000001886. doi: 10.1097/JU.0000000000001886.
    PubMed     Abstract available


  56. WOLDU SL, Ng CK, Loo RK, Slezak JM, et al
    Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria.
    J Urol. 2021;205:1387-1393.
    PubMed     Abstract available


  57. HASHEM A, Abol-Enein H, Laymon M, Abdellutif MM, et al
    A Randomized Trial to Examine the Utility of Mebeverine on the Early Return of Continence Following Orthotopic Bladder Substitution.
    J Urol. 2021;205:1400-1406.
    PubMed     Abstract available


  58. MATULEWICZ RS, Basak R, Zambrano I, Dearing BA, et al
    Patterns of Current Cigarette Smoking, Quit Attempts and Cessation Counseling among Survivors of Smoking-Related and Nonsmoking-Related Urological Malignancies: A Nationally Representative Cross-Sectional Analysis.
    J Urol. 2021;205:1444-1451.
    PubMed     Abstract available


  59. WYMER KM, Sharma V, Saigal CS, Chamie K, et al
    Cost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-Guerin-Unresponsive Carcinoma In Situ of the Bladder.
    J Urol. 2021;205:1326-1335.
    PubMed     Abstract available


    April 2021
  60. BREE KK, Hensley PJ, Westerman MB, Kokorovic A, et al
    Contemporary Rates of Gynecologic Organ Involvement in Females With Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy Following Neoadjuvant Chemotherapy.
    J Urol. 2021 Apr 19:101097JU0000000000001784. doi: 10.1097/JU.0000000000001784.
    PubMed     Abstract available


  61. BAUSCH K, Halbeisen FS, Aghlmandi S, Sutter SU, et al
    Reply by Authors.
    J Urol. 2021;205:998.
    PubMed    


  62. SOUNTOULIDES P, Pyrgidis N, Brookman-May S, Mykoniatis I, et al
    Does Ureteral Stenting Increase the Risk of Metachronous Upper Tract Urothelial Carcinoma in Patients with Bladder Tumors? A Systematic Review and Meta-analysis.
    J Urol. 2021;205:956-966.
    PubMed     Abstract available


  63. SHVERO A, Abu-Ghanem Y, Laufer M, Dotan ZA, et al
    Endoscopic Treatment for Large Multifocal Upper Tract Urothelial Carcinoma.
    J Urol. 2021;205:1039-1046.
    PubMed     Abstract available


    March 2021
  64. LUSTY A, Doiron RC, Booth CM, Whitehead M, et al
    No Outcome Differences after Cystectomy Between Patients with de Novo Muscle-Invasive Bladder Cancer Compared to Progressors: A Retrospective Population-Based Study.
    J Urol. 2021 Mar 30:101097JU0000000000001715. doi: 10.1097/JU.0000000000001715.
    PubMed     Abstract available


  65. YANAGISAWA T, Miki J, Sakanaka K, Fukuokaya W, et al
    Clinical Significance of Horizontal and Vertical Margin of En Bloc Resection for Non-Muscle Invasive Bladder Cancer.
    J Urol. 2021 Mar 29:101097JU0000000000001735. doi: 10.1097/JU.0000000000001735.
    PubMed     Abstract available



  66. Erratum: Perceptions of Link between Smoking and Bladder Cancer among United States Adults.
    J Urol. 2021;205:942.
    PubMed    



  67. Erratum: Microbiome of Catheter Collected Urine in Males with Bladder Cancer According to Disease Stage.
    J Urol. 2021;205:942.
    PubMed    


  68. DAS A, Cohen JE, Ko OS, Jordan BJ, et al
    Surgeon Scorecards Improve Muscle Sampling on Transurethral Resection of Bladder Tumor and Recurrence Outcomes in Patients with Nonmuscle Invasive Bladder Cancer.
    J Urol. 2021;205:693-700.
    PubMed     Abstract available


  69. TAGUCHI S, Tambo M, Watanabe M, Machida H, et al
    Prospective Validation of Vesical Imaging-Reporting and Data System Using a Next-Generation Magnetic Resonance Imaging Scanner-Is Denoising Deep Learning Reconstruction Useful?
    J Urol. 2021;205:686-692.
    PubMed     Abstract available


  70. SWAMI U, Haaland B, Kessel A, Nussenzveig R, et al
    Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma.
    J Urol. 2021;205:709-717.
    PubMed     Abstract available


    February 2021
  71. BHAT A, Kwon D, Soodana-Prakash N, Mouzannar A, et al
    Surveillance Intensity in Intermediate Risk Nonmuscle Invasive Bladder Cancer: Revisiting the Optimal Timing and Frequency of Cystoscopy.
    J Urol. 2021 Feb 22:101097JU0000000000001689. doi: 10.1097/JU.0000000000001689.
    PubMed     Abstract available


  72. ZHU D, Srivastava A, Agalliu I, Fram E, et al
    Finasteride Use and Risk of Bladder Cancer in a Multiethnic Population.
    J Urol. 2021 Feb 22:101097JU0000000000001694. doi: 10.1097/JU.0000000000001694.
    PubMed     Abstract available


  73. MICHELLE R, Liguori G, Trombetta C
    Antimicrobial Prophylaxis for Postoperative Urinary Tract Infections in Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-analysis. Letter.
    J Urol. 2021 Feb 12:101097JU0000000000001649. doi: 10.1097/JU.0000000000001649.
    PubMed    


  74. ZIBELMAN M, Asghar AM, Parker DC, O'Neill J, et al
    Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pT0 Bladder Cancer: A Prospective Trial.
    J Urol. 2021 Feb 4:101097JU0000000000001602. doi: 10.1097/JU.0000000000001602.
    PubMed     Abstract available


  75. FURRER MA, Kiss B, Studer UE, Wuethrich PY, et al
    Seminal Vesical Sparing Cystectomy in Bladder Cancer Patients is Feasible with Good Functional Results without Impairing Oncological Outcomes: A Longitudinal Long-Term Propensity-Matched Single Center Study.
    J Urol. 2021 Feb 3:101097JU0000000000001635. doi: 10.1097/JU.0000000000001635.
    PubMed     Abstract available


  76. GHOREIFI A, Djaladat H
    Re: Intra-Operative Ureteral Stent Use at Radical Cystectomy is Associated with Higher 30-Day Complication RatesDonat SM, Tan KS, Jibara G, Dalbagni G, Arslan Carlon V, Sandhu J J Urol 2020; doi:10.1097/JU.0000000000001329.
    J Urol. 2021;205:335-336.
    PubMed    


  77. DONAT SM, Tan KS, Jibara G, Dalbagni G, et al
    Intraoperative Ureteral Stent Use at Radical Cystectomy is Associated with Higher 30-Day Complication Rates.
    J Urol. 2021;205:483-490.
    PubMed     Abstract available


  78. CACCIAMANI GE, Medina L, Lin-Brande M, Tafuri A, et al
    Timing, Patterns and Predictors of 90-Day Readmission Rate after Robotic Radical Cystectomy.
    J Urol. 2021;205:491-499.
    PubMed     Abstract available


  79. ELSAYED AS, Gibson S, Jing Z, Wijburg C, et al
    Rates and Patterns of Recurrences and Survival Outcomes after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium.
    J Urol. 2021;205:407-413.
    PubMed     Abstract available


  80. GALLIOLI A, Territo A, Mercade A, Fontana M, et al
    The Impact of Ureteroscopy following Computerized Tomography Urography in the Management of Upper Tract Urothelial Carcinoma.
    J Urol. 2021;205:392-399.
    PubMed     Abstract available


  81. WEI XX, Werner L, Teo MY, Rosenberg JE, et al
    Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma.
    J Urol. 2021;205:414-419.
    PubMed     Abstract available


  82. CHESNUT GT, Tin AL, Sjoberg DD, Jang B, et al
    Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes following Radical Cystectomy.
    J Urol. 2021;205:400-406.
    PubMed     Abstract available


    January 2021
  83. MATULAY JT, Li R, Hensley PJ, Brooks NA, et al
    Contemporary Outcomes of Patients with Non-Muscle Invasive Bladder Cancer Treated with BCG Therapy: Implications for Clinical Trial Design.
    J Urol. 2021 Jan 27:101097JU0000000000001633. doi: 10.1097/JU.0000000000001633.
    PubMed     Abstract available


  84. YANAGISAWA T, Miki J, Yorozu T, Iwatani K, et al
    Vertical Lamina Propria Invasion Diagnosed by En Bloc Transurethral Resection is a Significant Predictor of Progression for pT1 Bladder Cancer.
    J Urol. 2021 Jan 27:101097JU0000000000001630. doi: 10.1097/JU.0000000000001630.
    PubMed     Abstract available


  85. WEIN AJ
    Voiding Function and Dysfunction, Bladder Physiology and Pharmacology, and Female Urology.
    J Urol. 2021;205:309-312.
    PubMed    


  86. MEEKS JJ
    Editorial Comment.
    J Urol. 2021;205:107.
    PubMed    


  87. HATAKEYAMA S, Hamano I, Ohyama C
    Editorial Comment.
    J Urol. 2021;205:107.
    PubMed    


  88. HAUTMANN RE, Volkmer B, Egghart G, Frohneberg D, et al
    Functional Outcome and Complications following Ileal Neobladder Reconstruction in Male Patients without Tumor Recurrence. More than 35 Years of Experience from a Single Center.
    J Urol. 2021;205:174-182.
    PubMed     Abstract available


    December 2020
  89. PETRUZELLA S, Bochner BH, Kenney J, Whiting K, et al
    Examining the Accuracy of Self-Reported Smoking-Related Exposure Among Recently Diagnosed Non-muscle Invasive Bladder Cancer Patients.
    J Urol. 2020 Dec 24:101097JU0000000000001571. doi: 10.1097/JU.0000000000001571.
    PubMed     Abstract available


  90. KIRSCHNER AN, Wang J, Rajkumar-Calkins A, Neuzil KE, et al
    Intravesical Anti-PD-1 Immune Checkpoint Inhibition Treats Urothelial Bladder Cancer in a Mouse Model.
    J Urol. 2020 Dec 24:101097JU0000000000001576. doi: 10.1097/JU.0000000000001576.
    PubMed     Abstract available


  91. BAUSCH K, Halbeisen FS, Aghlmandi S, Sutter SU, et al
    Antimicrobial Prophylaxis for Postoperative Urinary Tract Infections in Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-analysis.
    J Urol. 2020 Dec 7:101097JU0000000000001513. doi: 10.1097/JU.0000000000001513.
    PubMed     Abstract available


  92. CHANG SS
    Re: Impact of Adjuvant Chemotherapy in Patients with Adverse Features and Variant Histology at Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder: Does Histologic Subtype Matter?
    J Urol. 2020;204:1378.
    PubMed    


  93. MORI K, Abufaraj M, Mostafaei H, Quhal F, et al
    A Systematic Review and Meta-Analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy.
    J Urol. 2020;204:1129-1140.
    PubMed     Abstract available


    November 2020
  94. DE JONG FC, Hoedemaeker RF, Kvikstad V, Mensink JTM, et al
    T1-Substaging of Non-muscle Invasive Bladder Cancer is Associated with BCG-Failure and Improves Patient Stratification at Diagnosis.
    J Urol. 2020 Nov 16:101097JU0000000000001422. doi: 10.1097/JU.0000000000001422.
    PubMed     Abstract available


  95. YIN G, Tang J, Wang L
    Re: A Urine Based Genomic Assay to Triage Patients with Hematuria for CystoscopyK. E. M. van Kessel, J. J. de Jong, A. C. J. Ziel-van der Made, H. Roshani, S. M. Haensel, J. H. Wolterbeek, E. R. Boeve, E. H. G. M. Oomens, N. J. van Casteren, M. Krispi
    J Urol. 2020;204:1062.
    PubMed    


  96. HANNA PT, Peterson M, Albersheim J, Drawz P, et al
    Acute Kidney Injury following Enhanced Recovery after Surgery in Patients Undergoing Radical Cystectomy.
    J Urol. 2020;204:982-988.
    PubMed     Abstract available


  97. WANG DS
    Re: Epidural Anesthesia is Associated with Increased Complications in Cystectomy Patients: A NSQIP Analysis.
    J Urol. 2020;204:1072-1073.
    PubMed    


    October 2020
  98. MYRIE AK, Matulewicz RS
    Perceptions of the Link Between Smoking and Bladder Cancer Among United States Adults.
    J Urol. 2020 Oct 14:101097JU0000000000001415. doi: 10.1097/JU.0000000000001415.
    PubMed    


  99. SCHMIDT A, Warmann SW, Eckert F, Ellerkamp V, et al
    The Role of Reconstructive Surgery and Brachytherapy in Pediatric Bladder/Prostate Rhabdomyosarcoma.
    J Urol. 2020;204:825-834.
    PubMed     Abstract available


  100. ALMASSI N, Cha EK, Vertosick EA, Huang C, et al
    Trends in Management and Outcomes among Patients with Urothelial Carcinoma Undergoing Radical Cystectomy from 1995 to 2015: The Memorial Sloan Kettering Experience.
    J Urol. 2020;204:677-684.
    PubMed     Abstract available


  101. CACCIAMANI GE, Ghodoussipour S, Mari A, Gill KS, et al
    Association between Smoking Exposure, Neoadjuvant Chemotherapy Response and Survival Outcomes following Radical Cystectomy: Systematic Review and Meta-Analysis.
    J Urol. 2020;204:649-660.
    PubMed     Abstract available


    September 2020
  102. CHANG SS
    Re: Bacillus Calmette-Guerin (BCG) Therapy Lowers the Incidence of Alzheimer's Disease in Bladder Cancer Patients.
    J Urol. 2020 Sep 21:101097JU000000000000128202.
    PubMed    


  103. CHANG SS
    Re: Care Quality and Variability in the Use of Intravesical Therapy for Initial Treatment of Nonmuscle Invasive Bladder Cancer within a Large, Diverse Integrated Delivery System.
    J Urol. 2020 Sep 21:101097JU000000000000128201.
    PubMed    


  104. ATALA A
    Re: A Genetically Defined Disease Model Reveals That Urothelial Cells Can Initiate Divergent Bladder Cancer Phenotypes.
    J Urol. 2020 Sep 21:101097JU000000000000128501.
    PubMed    


  105. REGMI SK, Kalapara A, Konety BR
    The Need for Interim Assessment of Neoadjuvant Chemotherapy Response for Muscle Invasive Bladder Cancer: Can We Help Prevent Definitive Treatment Delay in Non-responders?
    J Urol. 2020 Sep 18:101097JU0000000000001381. doi: 10.1097/JU.0000000000001381.
    PubMed    


  106. LAVIANA AA, Stone BV, Avulova S
    Editorial Comment.
    J Urol. 2020;204:458-459.
    PubMed    


  107. KRETSCHMER A
    Editorial Comment.
    J Urol. 2020;204:458.
    PubMed    


  108. CHANG SS
    Editorial Comment.
    J Urol. 2020;204:449.
    PubMed    


  109. CADEDDU JA
    Re: Long-Term Oncological Outcomes from an Early Phase Randomised Controlled Three-Arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL).
    J Urol. 2020;204:598.
    PubMed    


  110. DASON S, Cha EK, Falavolti C, Vertosick EA, et al
    Late Recurrences Following Radical Cystectomy Have Distinct Prognostic and Management Considerations.
    J Urol. 2020;204:460-465.
    PubMed     Abstract available


    August 2020
  111. ORESTA B, Braga D, Lazzeri M, Frego N, et al
    The Microbiome of Catheter-Collected Urine in Males with Bladder Cancer according to Disease Stage.
    J Urol. 2020 Aug 28:101097JU0000000000001336. doi: 10.1097/JU.0000000000001336.
    PubMed     Abstract available


  112. CHANG SS
    Re: Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial.
    J Urol. 2020 Aug 21:101097JU0000000000001260. doi: 10.1097/JU.0000000000001260.
    PubMed    


  113. CHANG SS
    Re: Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2020 Aug 21:101097JU000000000000126001.
    PubMed    


  114. CHANG SS
    Re: Cigarette Smoking is Associated with Adverse Pathological Response and Increased Disease Recurrence amongst Patients with Muscle-Invasive Bladder Cancer Treated with Cisplatin-Based Neoadjuvant Chemotherapy and Radical Cystectomy: A Single-Centre
    J Urol. 2020 Aug 21:101097JU000000000000126002.
    PubMed    


  115. HAJIRAN A, Azizi M, Aydin AM, Zemp L, et al
    Pathologic and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed with Cystectomy with or Without Neoadjuvant Chemotherapy.
    J Urol. 2020 Aug 12:101097JU0000000000001325. doi: 10.1097/JU.0000000000001325.
    PubMed     Abstract available


  116. LIM A, Gregg JR
    Editorial Comment.
    J Urol. 2020;204:245-246.
    PubMed    


  117. CHENG L
    Editorial Comment.
    J Urol. 2020;204:246.
    PubMed    


  118. DE JONG JJ, Liu Y, Boorjian SA, Bivalacqua TJ, et al
    A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Up Staging.
    J Urol. 2020;204:239-246.
    PubMed     Abstract available


  119. KIM DK, Kim JW, Ro JY, Lee HS, et al
    Plasmacytoid Variant Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis of Clinicopathological Features and Survival Outcomes.
    J Urol. 2020;204:215-223.
    PubMed     Abstract available


  120. CHANG SS
    Re: Smoking Cessation: A Report of the Surgeon General.
    J Urol. 2020;204:384.
    PubMed    


  121. DASON S, Wong NC, Donahue TF, Meier A, et al
    Utility of Routine Preoperative (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy.
    J Urol. 2020;204:254-259.
    PubMed     Abstract available


  122. DECASTRO GJ, Sui W, Pak JS, Lee SM, et al
    A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guerin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
    J Urol. 2020;204:247-253.
    PubMed     Abstract available


    July 2020
  123. OSTERMAN CK, Deal AM, McCloskey H, Nyrop KA, et al
    Impairment and Longitudinal Recovery of Older Adults Treated with Radical Cystectomy for Muscle-Invasive Bladder Cancer.
    J Urol. 2020 Jul 27:101097JU0000000000001323. doi: 10.1097/JU.0000000000001323.
    PubMed     Abstract available


  124. CHANG SS
    Re: STAG2 is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2020 Jul 27:101097JU000000000000121902.
    PubMed    


  125. ATALA A
    Re: The CUL4B-miR-372/373-PIK3CA-AKT Axis Regulates Metastasis in Bladder Cancer.
    J Urol. 2020 Jul 27:101097JU000000000000122201.
    PubMed    


  126. TAN WS, Kelly JD
    Editorial Comment.
    J Urol. 2020;204:56-57.
    PubMed     Abstract available


  127. SHKOLYAR E, Mach KE, Liao JC
    Editorial Comment.
    J Urol. 2020;204:56.
    PubMed    


  128. MORI K, Mostafaei H, Enikeev DV, Lysenko I, et al
    Differential Effect of Sex on Outcomes after Radical Surgery for Upper Tract and Bladder Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    J Urol. 2020;204:58-62.
    PubMed     Abstract available


  129. VAN KESSEL KEM, de Jong JJ, Ziel-van der Made ACJ, Roshani H, et al
    A Urine Based Genomic Assay to Triage Patients with Hematuria for Cystoscopy.
    J Urol. 2020;204:50-57.
    PubMed     Abstract available


  130. CHANG SS
    Re: Adjuvant Chemotherapy vs Observation for Patients with Adverse Pathologic Features at Radical Cystectomy Previously Treated with Neoadjuvant Chemotherapy.
    J Urol. 2020;204:184.
    PubMed    


    June 2020
  131. CHANG SS
    Re: National Cancer Database Comparison of Radical Cystectomy vs Chemoradiotherapy for Muscle-Invasive Bladder Cancer: Implications of Using Clinical vs Pathologic Staging.
    J Urol. 2020 Jun 30:101097JU0000000000001175. doi: 10.1097/JU.0000000000001175.
    PubMed    


  132. CHANG SS
    Re: Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer.
    J Urol. 2020 Jun 30:101097JU000000000000117501.
    PubMed    


  133. ATALA A
    Re: Therapeutically Actionable PAK4 is Amplified, Overexpressed, and Involved in Bladder Cancer Progression.
    J Urol. 2020 Jun 18:101097JU000000000000117901.
    PubMed    


  134. CHANG SS
    Re: The Impact of Non-Urothelial Variant Histology on Oncological Outcomes following Radical Cystectomy.
    J Urol. 2020;203:1060.
    PubMed    


  135. SZYMANSKI KM, Misseri R, Whittam B, Hollowell N, et al
    Additional Surgeries after Bladder Augmentation in Patients with Spina Bifida in the 21st Century.
    J Urol. 2020;203:1207-1213.
    PubMed     Abstract available


  136. FOERSTER B, Abufaraj M, Petros F, Azizi M, et al
    Efficacy of Preoperative Chemotherapy for High Risk Upper Tract Urothelial Carcinoma.
    J Urol. 2020;203:1101-1108.
    PubMed     Abstract available


    May 2020
  137. GRIEBLING TL
    Re: Rate and Determinants of Completing Neoadjuvant Chemotherapy in Medicare Beneficiaries with Bladder Cancer: A SEER-Medicare Analysis.
    J Urol. 2020 May 13:101097JU000000000000110204.
    PubMed    


  138. CHANG SS
    Re: Assessment of Quality of Life, Information, and Supportive Care Needs in Patients with Muscle and Non-Muscle Invasive Bladder Cancer across the Illness Trajectory.
    J Urol. 2020 May 12:101097JU000000000000111402.
    PubMed     Abstract available


  139. ATALA A
    Re: A Genetically Defined Disease Model Reveals that Urothelial Cells Can Initiate Divergent Bladder Cancer Phenotypes.
    J Urol. 2020 May 12:101097JU0000000000001117. doi: 10.1097/JU.0000000000001117.
    PubMed    


  140. CHANG SS
    Re: Association between Treatment of Superficial Bladder Cancer and 10-Year Mortality in Older Adults with Multiple Chronic Conditions.
    J Urol. 2020 May 12:101097JU000000000000111401.
    PubMed    


  141. CHANG SS
    Re: PD-L1 Expression in Tumor Cells and the Immunologic Milieu of Bladder Carcinomas: A Pathologic Review of 165 Cases.
    J Urol. 2020;203:880.
    PubMed    


  142. WITJES JA
    Editorial Comment.
    J Urol. 2020;203:908-909.
    PubMed    


    April 2020
  143. ROUPRET M, Gontero P, McCracken SRC, Dudderidge T, et al
    Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Non Muscle Invasive Bladder Cancer Follow up: A Blinded, Prospective Cohort, Multicentric European Study.
    J Urol. 2020 Apr 21:101097JU0000000000001084. doi: 10.1097/JU.0000000000001084.
    PubMed     Abstract available


  144. ATALA A
    Re: Hypermethylation of FOXA1 and Allelic Loss of PTEN Drive Squamous Differentiation and Promote Heterogeneity in Bladder Cancer.
    J Urol. 2020 Apr 9:101097JU0000000000001058. doi: 10.1097/JU.0000000000001058.
    PubMed    


  145. CHANG SS
    Re: Bladder Preservation with Twice-a-Day Radiation plus Fluorouracil/Cisplatin or Once Daily Radiation plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
    J Urol. 2020 Apr 9:101097JU0000000000001055. doi: 10.1097/JU.0000000000001055.
    PubMed    


  146. BECERRA MF, Venkatramani V, Reis IM, Soodana-Prakash N, et al
    Health-Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial - A Multi-Institutional Randomized Trial Comparing Robot versus Open Radical Cystectomy.
    J Urol. 2020 Apr 9:101097JU0000000000001029. doi: 10.1097/JU.0000000000001029.
    PubMed     Abstract available


  147. CHANG SS
    Re: Implementation of a Perioperative Venous Thromboembolism Prophylaxis Program for Patients Undergoing Radical Cystectomy on an Enhanced Recovery after Surgery Protocol.
    J Urol. 2020;203:660.
    PubMed    


    March 2020
  148. SHARMA V, Wymer KM, Borah BJ, Saigal CS, et al
    Cost-Effectiveness of Maintenance BCG for Intermediate and High Risk Non-Muscle Invasive Bladder Cancer.
    J Urol. 2020 Mar 19:101097JU0000000000001023. doi: 10.1097/JU.0000000000001023.
    PubMed     Abstract available


  149. CHANG SS
    Re: The Challenges of Bacillus of Calmette-Guerin (BCG) Therapy for High Risk Non Muscle Invasive Bladder Cancer Treatment in Older Patients.
    J Urol. 2020 Mar 17:101097JU000000000000099902.
    PubMed    


  150. NABAVIZADEH R, Joshi SS
    Editorial Comment.
    J Urol. 2020;203:511.
    PubMed    


  151. MONTORSI F, Moschini M, Gallina A, Briganti A, et al
    Re: Ten-Year Oncologic Outcomes following Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium.
    J Urol. 2020;203:624.
    PubMed    


  152. MULLER G, Butea-Bocu M, Brock O, Hanske J, et al
    Association between Development of Metabolic Acidosis and Improvement of Urinary Continence after Ileal Neobladder Creation.
    J Urol. 2020;203:585-590.
    PubMed     Abstract available


  153. ZHANG JH, Ericson KJ, Thomas LJ, Knorr J, et al
    Large Single Institution Comparison of Perioperative Outcomes and Complications of Open Radical Cystectomy, Intracorporeal Robot-Assisted Radical Cystectomy and Robotic Extracorporeal Approach.
    J Urol. 2020;203:512-521.
    PubMed     Abstract available


  154. VENKATRAMANI V, Reis IM, Castle EP, Gonzalgo ML, et al
    Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup.
    J Urol. 2020;203:522-529.
    PubMed     Abstract available


    February 2020
  155. INABA H, Kimura T, Onuma H, Sato S, et al
    Tumor Location and Pathological Features of Latent and Incidental Prostate Cancer in Contemporary Japanese Men.
    J Urol. 2020 Feb 18:101097JU0000000000000804. doi: 10.1097/JU.0000000000000804.
    PubMed     Abstract available


  156. ATALA A
    Re: 5-Methylcytosine Promotes Pathogenesis of Bladder Cancer through Stabilizing mRNAs.
    J Urol. 2020 Feb 12:101097JU0000000000000781. doi: 10.1097/JU.0000000000000781.
    PubMed    


  157. ATALA A
    Re: Inhibition of a G9a/DNMT Network Triggers Immune-Mediated Bladder Cancer Regression.
    J Urol. 2020 Feb 12:101097JU000000000000078101.
    PubMed    


  158. WEINER AB, Kundu SD
    Editorial Comment.
    J Urol. 2020;203:290-291.
    PubMed    


  159. CHANG SS
    Re: Effectiveness of Adjuvant Chemotherapy after Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-Invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis.
    J Urol. 2020;203:250.
    PubMed    


    January 2020
  160. GARNIER S, Vendrell J, Boillot B, Karsenty G, et al
    Malignancy after Augmentation Enterocystoplasty: A Nationwide Study of Natural History, Prognosis and Oncogene Panel Analysis.
    J Urol. 2020 Jan 20:101097JU0000000000000752. doi: 10.1097/JU.0000000000000752.
    PubMed     Abstract available


  161. ATALA A
    Re: Epigenetic Loss of AOX1 Expression via EZH2 Leads to Metabolic Deregulations and Promotes Bladder Cancer Progression.
    J Urol. 2020 Jan 13:101097JU000000000000073202.
    PubMed    


  162. CHANG SS
    Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine plus Cisplatin in Patients with Muscle-Invasive Bladder Cancer.
    J Urol. 2020 Jan 13:101097JU0000000000000729. doi: 10.1097/JU.0000000000000729.
    PubMed    


  163. CHANG SS
    Re: Predictive Factors for Residual Cancer in Second Transurethral Resection for Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2020 Jan 13:101097JU000000000000072902.
    PubMed    


  164. SIEGEL C
    Re: Delayed (18)F FDG PET/CT Imaging in the Assessment of Residual Tumors after Transurethral Resection of Bladder Cancer.
    J Urol. 2020 Jan 7:101097JU0000000000000718. doi: 10.1097/JU.0000000000000718.
    PubMed    


  165. GRIEBLING TL
    Re: Frailty as a Predictor of Complications after Radical Cystectomy: A Prospective Study of Various Preoperative Assessments.
    J Urol. 2020;203:9.
    PubMed    


  166. ALDHAAM NA, Elsayed AS, Jing Z, Richstone L, et al
    Neoadjuvant Chemotherapy is Not Associated with Adverse Perioperative Outcomes after Robot-Assisted Radical Cystectomy: A Case for Increased Use from the IRCC.
    J Urol. 2020;203:57-61.
    PubMed     Abstract available


  167. CHECK DK, Leo MC, Banegas MP, Bulkley JE, et al
    Decision Regret Related to Urinary Diversion Choice among Patients Treated with Cystectomy.
    J Urol. 2020;203:159-163.
    PubMed     Abstract available


    December 2019
  168. STEINBERG RL, Thomas LJ, Brooks N, Mott SL, et al
    Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy of Non-muscle Invasive Bladder Cancer.
    J Urol. 2019 Dec 10:101097JU0000000000000688. doi: 10.1097/JU.0000000000000688.
    PubMed     Abstract available


  169. CHANG SS
    Re: Radiofrequency-Induced Thermo-Chemotherapy Effect versus a Second Course of Bacillus Calmette-Guerin or Institutional Standard in Patients with Recurrence of Non-Muscle-Invasive Bladder Cancer following Induction or Maintenance Bacillus Calmette-G
    J Urol. 2019 Dec 3:101097JU0000000000000676. doi: 10.1097/JU.0000000000000676.
    PubMed    


  170. WEIN AJ
    Re: Long-Term Follow-Up after Cystectomy for Bladder Pain Syndrome: Pain Status, Sexual Function and Quality of Life.
    J Urol. 2019;202:1101-1102.
    PubMed    


  171. LENIS AT
    Editorial Comment.
    J Urol. 2019;202:1134-1135.
    PubMed    


  172. ALBERSHEIM J, Sathianathen NJ, Zabell J, Renier J, et al
    Skeletal Muscle and Fat Mass Indexes Predict Discharge Disposition after Radical Cystectomy.
    J Urol. 2019;202:1143-1149.
    PubMed     Abstract available


  173. SIGHINOLFI MC, Rocco B, Micali S, Bianchi G, et al
    Re: Accurate Quantification of Residual Cancer Cells in Pelvic Washing Reveals Association with Cancer Recurrence following Robot-Assisted Radical Cystectomy.
    J Urol. 2019;202:1271-1272.
    PubMed    


  174. RASKOLNIKOV D, Brown B, Holt SK, Ball AL, et al
    Reduction of Pain during Flexible Cystoscopy: A Systematic Review and Meta-Analysis.
    J Urol. 2019;202:1136-1142.
    PubMed     Abstract available


  175. AL HUSSEIN AL AWAMLH B, Shoag JE, Ravikumar V, Posada L, et al
    Association of Smoking and Death from Genitourinary Malignancies: Analysis of the National Longitudinal Mortality Study.
    J Urol. 2019;202:1248-1254.
    PubMed     Abstract available


    November 2019
  176. SCHAEFFER EM
    Re: Reduced Recurrence of Low-Grade Papillary Bladder Tumors Associated with Asymptomatic Bacteriuria.
    J Urol. 2019;202:849.
    PubMed    


  177. ATALA A
    Re: Recurrent Activating Mutations of PPARgamma Associated with Luminal Bladder Tumors.
    J Urol. 2019;202:869.
    PubMed    


  178. PEYTON CC, Reich RR, Tang D, Alford B, et al
    Identifying and Codifying Complications after Radical Cystectomy: Comparison of Administrative Diagnostic and Procedure Codes, and Clinical Chart Review.
    J Urol. 2019;202:913-919.
    PubMed     Abstract available


  179. HUSSEIN AA, Elsayed AS, Aldhaam NA, Jing Z, et al
    Ten-Year Oncologic Outcomes Following Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium.
    J Urol. 2019;202:927-935.
    PubMed     Abstract available


  180. MCALPINE K, Lavallee LT, Stacey D, Moodley P, et al
    Development and Acceptability Testing of a Patient Decision Aid for Urinary Diversion with Radical Cystectomy.
    J Urol. 2019;202:1001-1007.
    PubMed     Abstract available


    October 2019
  181. LOTAN Y
    Re: Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guerin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.
    J Urol. 2019 Oct 25:101097JU0000000000000625. doi: 10.1097/JU.0000000000000625.
    PubMed    


  182. MONTORSI F, Moschini M, Briganti A
    Re: Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guerin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.
    J Urol. 2019 Oct 24:101097JU0000000000000624. doi: 10.1097/JU.0000000000000624.
    PubMed    


  183. CHANG SS
    Re: Occupation and Bladder Cancer Phenotype: Identification of Workplace Patterns That Increase the Risk of Advanced Disease beyond Overall Incidence.
    J Urol. 2019 Oct 16:101097JU0000000000000599. doi: 10.1097/JU.0000000000000599.
    PubMed    


  184. RITCH CR, Velasquez MC, Kwon D, Becerra MF, et al
    Utility and Validation of the AUA/SUO Risk Grouping for Non-muscle Invasive Bladder Cancer in a Contemporary Cohort.
    J Urol. 2019 Oct 14:101097JU0000000000000593. doi: 10.1097/JU.0000000000000593.
    PubMed     Abstract available


  185. LABBATE C, Werntz RP, Adamic B, Steinberg GD, et al
    The Impact of Omission of Intraoperative Frozen Section Prior to Orthotopic Neobladder Reconstruction.
    J Urol. 2019;202:763-769.
    PubMed     Abstract available


  186. SINGLA N
    Editorial Comment.
    J Urol. 2019;202:688.
    PubMed    


  187. SEFIK E, Bozkurt IH, Basmaci I, Celik S, et al
    Re: Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled Trial.
    J Urol. 2019;202:819.
    PubMed    


  188. LUO Y, Wang X, Xiao Y
    Re: Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled Trial.
    J Urol. 2019;202:819-820.
    PubMed    


    September 2019
  189. LIEM EI, Oddens JR, Vernooij R, Li R, et al
    The Role of Fluorescence in Situ Hybridization for Predicting Recurrence after Adjuvant Bacillus Calmette-Guerin in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer Patients: A Systematic Review and Meta-Analysis of Individual Patient Da
    J Urol. 2019 Sep 24:101097JU0000000000000566. doi: 10.1097/JU.0000000000000566.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: